The global liquid biopsy market is projected to grow significantly, with an estimated value of USD 35.3 billion by 2033, up from USD 10.3 billion in 2023, reflecting a compound annual growth rate ...
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications ...
Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today ...
An analyst from Goldman Sachs has decided to maintain their Buy rating on Guardant Health, which currently sits at a price ...
Q1 2024 Earnings Call Transcript May 12, 2024 SOPHiA GENETICS SA isn’t one of the 30 most popular stocks among hedge funds at ...
Q1 2024 Earnings Call May 10, 2024 Guardant Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end ...
Cancer biopsy tests sold to biopharma companies for use in clinical studies, meanwhile, grew 37% to 8,450. “We also saw continued progress in our EMR integration efforts which streamlines orders and ...
Ultrasound imaging offers a valuable and noninvasive way to find and monitor cancerous tumors. However, much of the most ...
Healthcare Asia on MSN2d
Enteral feeding devices market size to grow by 6.42% CAGR until 2027The market is expected to grow by $1.36b within the forecast period. The global enteral feeding devices market size is ...
There’s a penny stock that’s recently grabbed the headlines for the right reasons. Is it time for me to think again and buy some of the shares? The post Is it time to do a 360 degree u-turn and buy ...
Having examined the options trading patterns of Guardant Health, our attention now turns directly to the company. This shift ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results